Contrave Weight Loss Drug Patents Infringed by Generic Maker, Court Rules
A Delaware federal judge ruled on Oct. 13 that Actavis Laboratories FL Inc. infringed three patents with a planned generic version of the weight-loss drug Contrave, rejecting the company's defense as a "classic case" of hindsight bias.
Your article was successfully shared with the contacts you provided.
This premium content is locked for Delaware Business Court Insider subscribers only.
Subscribe now to enjoy unlimited access to Delaware Business Court Insider content,
5 free articles* across the ALM Network every 30 days,
Exclusive access to other free ALM publications
And exclusive discounts on ALM events and publications.
*May exclude premium content Already have an account? Sign In Now
Interested in customizing your subscription with Law.com All Access?
Contact our Sales Professionals at 1-855-808-4530 or send an email to firstname.lastname@example.org to learn more.
Tom McParland of Delaware Law Weekly can be contacted at 215-557-2485 or at email@example.com. Follow him on Twitter @TMcParlandTLI.
In a nearly full reversal of a 2015 lower court ruling, an appeals panel has ruled that Susan Kassapian, a principal administrative law judge from 2009-13, stated several claims that should survive the city’s motion to dismiss.
A task force reconvened by Chief Judge Janet DiFiore to recommend changes to the state’s constitution will be co-chaired by her husband, Dennis Glazer, a retired Davis Polk & Wardwell partner and Justice Alan Scheinkman, the administrative judge of the state’s Ninth Judicial District.
Law Offices of Mark E. Salomone
2 Oliver St #608
Gary Martin Hays & Associates
235 Peachtree St NE #400
The Law Firm Of Jonathan C. Reiter
350 5th Ave
Presented by BigVoodoo
ALM Legal Publication Newsletters
Sign Up Today and Never Miss Another Story.
As part of your digital membership, you can sign up for an unlimited number of a wide range of complimentary newsletters.
Visit your My Account page to make your selections. Get the timely legal news and critical analysis you cannot afford to miss.
Tailored just for you. In your inbox. Every day.